Differential Associations of Inflammatory and Endothelial Biomarkers with Disease Activity in Rheumatoid Arthritis of Short Duration
Table 4
Biochemical markers of inflammatory activity and endothelial activation according to DAS28.
Control group ()
RA patients with low DAS28∧ ()
RA patients with high DAS28∧ ()
P
valueua
P adjusteda
Nv
Mean (SD)
Nv
Mean (SD)
Nv
Mean (SD)
ADMA, µmol/L
28
0.67 (0.18)
15
0.69 (0.17)
11
0.88 (0.19)*#‡¥
0.007
0.027
SDMA, µmol/L
26
0.62 (0.18)
15
0.58 (0.18)
11
0.53 (0.13)
0.404
0.220
ADMA/SDMA ratio
26
1.17 (0.47)
15
1.27 (0.4)*
11
1.77 (0.69)*‡¥
0.006
0.020
sVCAM-1, ng/mL
28
613.3 (148.4)
15
779.98 (203.67)*‡
11
685.61 (156.74)
0.008
0.033
MCP-1, pg/mL
28
262.4 (90.73)
15
336.13 (87.84)
11
493.47 (379.53)*‡
0.015
0.030
sE-selectin, ng/mL
28
12.45 (8.02)
15
14.98 (5.8)
11
22.03 (10.9)*‡¥
0.006
0.047
vWf, %
27
73.73 (22.39)
15
102.76 (44.78)*‡
11
121.19 (54.51)*‡
0.008
0.019
Osteoprotegerin, pmol/L
28
4.01 (1.06)
15
4.89 (0.98)
11
5.65 (1.76)*‡
0.001
0.038
Pentraxin-3, ng/mL
28
0.45 (0.17)
15
0.73 (0.27)*‡
11
0.75 (0.31)*‡
0.001
0.002
ESR, mm/h
29
6.58 (4.79)
14
21.64 (16.94)*‡
11
61.27 (22.93)*#‡¥
<0.001
<0.001
hsCRP, mg/L
29
0.84 (0.71)
15
4.48 (6.2)
11
32.9 (32.84)*#‡¥
0.004
<0.001
TNF-α, pg/mL
28
1.78 (1.07)
15
2.06 (0.53)
11
3.33 (1.24)*#‡¥
<0.001
<0.001
Interleukin-6, pg/mL
28
0.86 (0.41)
15
4.54 (5.11)*
11
14.93 (8.72)*#‡¥
<0.001
<0.001
Data are shown as unadjusted means (SD). ∧Low DAS28 = (2.6–5.1); high DAS28 = (>5.1). Nv: valid cases; RA: rheumatoid arthritis; ADMA: asymmetric dimethyl-L-arginine; SDMA: symmetric dimethyl-L-arginine; sVCAM-1: soluble vascular cell adhesion molecule-1; MCP-1: monocyte chemotactic protein-1; sE-selectin: soluble E-selectin; vWF: von Willebrand factor.
uaUnadjusted P value in ANOVA (GLM models). * versus control group and # versus RA patients with low disease activity in post hoc analyses for unadjusted ANOVA.
aAge-sex adjusted Pvalue for the defining groups of patients in ANOVA (GLM models)—type III sum of square (SS) was used. ‡ versus control group and ¥ versus RA patients with low disease activity in post hoc analyses for adjusted ANOVA.
